NCT06537596View on ClinicalTrials.gov

89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

August 31, 2026

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)

Single administration of 89Zr-TLX300-CDx

Trial Locations (1)

3051

RECRUITING

Precision Molecular Imaging & Theranostics Pty Ltd, Melbourne

All Listed Sponsors
lead

Telix Pharmaceuticals (Innovations) Pty Ltd

INDUSTRY

NCT06537596 - 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter